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Abstract
Background: Acute pulmonary embolism (APE) remains a diagnostic challenge due to a variable clinical
presentation and the lack of a reliable screening tool. MicroRNAs (miRNAs) regulate gene expression in a wide
range of pathophysiologic processes. Circulating miRNAs are emerging biomarkers in heart failure, type 2 diabetes
and other disease states; however, using plasma miRNAs as biomarkers for the diagnosis of APE is still unknown.
Methods: Thirty-two APE patients, 32 healthy controls, and 22 non-APE patients (reported dyspnea, chest pain, or
cough) were enrolled in this study. The TaqMan miRNA microarray was used to identify dysregulated miRNAs in
the plasma of APE patients. The TaqMan-based miRNA quantitative real-time reverse transcription polymerase chain
reactions were used to validate the dysregulated miRNAs. The receiver-operator characteristic (ROC) curve analysis
was conducted to evaluate the diagnostic accuracy of the miRNA identified as the candidate biomarker.
Results: Plasma miRNA-134 (miR-134) level was significantly higher in the APE patients than in the healthy controls
or non-APE patients. The ROC curve showed that plasma miR-134 was a specific diagnostic predictor of APE with
an area under the curve of 0.833 (95% confidence interval, 0.737 to 0.929; P < 0.001).
Conclusions: Our findings indicated that plasma miR-134 could be an important biomarker for the diagnosis of
APE. Because of this finding, large-scale investigations are urgently needed to pave the way from basic research to
clinical utilization.
Background
Acute pulmonary embolism (APE) is a common cardiovas-
cular emergency associated with a substantial morbidity
and mortality [1-3]. APE accounts for 50, 000 to 100, 000
deaths a year in the United States alone and approximately
10% of deaths in European hospitals [2,4]. The annual inci-
dence of APE in the United States and Europe is approxi-
mately 100 cases per 100, 000 individuals [2,4]. Despite the
morbidity associated with APE, the diagnosis is frequently
missed due to the variable clinical presentation [5,6].
Diagnostic testing for APE has been extensively studied
and ranges from biomarkers, such as the D-dimer assay,
to radiologic imaging, including CT angiography, venous
ultrasonography, and ultimately the gold standard of
pulmonary venous angiography. Although widely used as
a screening tool, D-dimer assays are sensitive but not
specific for detecting APE [7]. Novel biomarkers with
enhanced diagnostic accuracy would greatly facilitate the
diagnosis of APE [3].
In recent years, microRNAs (miRNAs) have been found
to play crucial roles in many cellular processes, such as
development, proliferation, differentiation and apoptosis.
MiRNAs are small, endogenous, single-stranded, noncod-
ing RNAs that regulate gene expression by hybridizing to
messenger RNAs (mRNAs) and inhibiting mRNA transla-
tion or promoting mRNA degradation [8-11]. The expres-
sion pattern of many miRNAs is reflective of various
pathophysiologic processes and underlies a large number of
diseases [8,12-14]. Circulating miRNAs are also emerging
as biomarkers in various diseases, including cancer, drug-
induced liver injury, heart failure, type 2 diabetes, stable
angina pectoris, and acute coronary artery syndromes
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Methods
Patient populations
Between February 2010 and July 2010, patients with a
high clinical probability of APE or those with a low/inter-
mediate probability and a positive D-dimer enzyme-
l i n k e di m m u n o s o r b e n ta s s a yt e s t( >5 0 0μg/L) in the
Shanghai Pulmonary Hospital, Tongji University under-
went testing to confirm APE. In accordance with existing
guidelines, these patients underwent a pulmonary angio-
graphy, contrast-enhanced computed tomography (CT)
pulmonary angiography or a ventilation-perfusion lung
scan, alone or in combination [24]. After the diagnosis of
APE, transthoracic echocardiography was performed to
detect (or exclude) right ventricular dysfunction (i.e.,
dilation of the right ventricle with an end-diastolic dia-
meter > 30 mm from the parasternal view, or the right
ventricle appearing larger than the left ventricle from the
subcostal or apical view) combined with right atrial
hypertension (absence of inspiratory collapse of the infer-
ior vena cava) in the absence of left ventricular or mitral
valve disease. Serum cardiac troponin I and BNP were
used as markers of myocardial injury or right ventricular
dysfunction, respectively. Afterwards, risk stratification
was conducted according to the guidelines [24]. Briefly,
high-risk APE is diagnosed if shock or hypotension
occurs. Intermediate-risk APE is confirmed when at least
one right ventricular dysfunction or one myocardial
injury marker is positive. Low-risk APE is confirmed
when all right ventricular dysfunction and myocardial
injury markers are negative [24]. During this period, 35
patients were confirmed to have an APE, and the 32
patients that gave informed consent were enrolled in this
study. The controls were 32 healthy volunteers. Twenty-
two patients (7 with pneumonia, 7 with unstable angina
pectoris, 3 with acute myocardial infarctions, 2 with lung
cancer, 1 with pleurisy, 1 with bronchiectasis and 1 with
asthma) who had reported dyspnea, chest pain, or cough
were consecutively recruited as the non-APE cases.
Approval was obtained from the ethical committees of
the Tongji University School of Medicine. All partici-
pants gave written informed consent before enrollment
in the study.
Plasma sampling and RNA isolation
At presentation, blood samples for miRNA detection
were collected in EDTA-K2 tubes and processed within
1 hour of collection. After a two-step centrifugation (4°C
at 820 × g for 10 min, then 4°C at 16000 × g for 10 min),
the supernatant was transferred to RNase/DNase-free
tubes and stored at -80°C.
T h et o t a lR N Aw a si s o l a t e df r o mt h ep l a s m au s i n ga
mirVana PARIS isolation kit (Ambion, Austin, Texas)
according to the manufacturer’s instructions for plasma
samples. Briefly, 400 μL of human plasma was used to
extract the total RNA. Each sample was eluted in 100 μL
of RNAse-free water. Spectrophotometric RNA quantifica-
tion of human plasma samples was not reliable because of
undetermined contaminants with an absorbance peak at
270 nm. However, the quantitative real-time reverse tran-
scription polymerase chain reaction (qRT-PCR) was not
affected [12]. Thus, all RNA samples were analyzed for
miR-16 expression, a stable endogenous reference miRNA,
to assess an approximate yield of RNA extraction and to
ensure that comparable amounts of starting material were
used in each reverse transcription reaction [25-29].
miRNA expression profile and validation
miRNAs were reverse-transcribed using the Megaplex
Primer Pools (Human Pools A v2.1 and B v2.0), and the
products were pre-amplified according to the Applied
Biosystems’ pre-amplification protocol. For the initial
screening, Human TaqMan miRNA microarrays (CardA
v2.1 and CardB v2.0, Applied Biosystems) covering 667
small, noncoding RNAs were performed on RNA from
the plasma of 10 randomly selected APE patients and
10 randomly selected healthy controls. All steps were
performed using a 7900HT Fast Real-Time PCR System
(Applied Biosystems, Foster City, CA); the results were
expressed as Cts and normalized to the calculated med-
ian Ct of each sample (ΔCt). The relative expression was
calculated using the comparative Ct method (2
-ΔΔCt).
The minimal microarray experiment compliant data were
exported to the Gene Expression Omnibus (Platform ID
GSE24149).
To minimize the number of false positives, only miRNAs
that differed from the healthy controls by more than
10-fold were considered for subsequent validation by
qRT-PCR. Single miRNA expression was determined
using TaqMan-based miRNA qRT-PCR (Applied Biosys-
tems, Foster City, CA) according to the manufacturer’s
instructions. Briefly, the 15-μL RT reaction master mix
was created with 5 μL of the total RNA sample isolated as
described above. qRT-PCR was carried out using the
7900HT Fast Real-Time PCR System on 20 μLo fP C R
master mix containing 10 μL of TaqMan 2× Universal
PCR Master Mix, 1 μL of TaqMan assay, 4 μL of RT pro-
ducts and 5 μL of ddH2O. The qRT-PCR reactions were
performed in triplicate, and the signal was collected at the
end of every cycle. Due to a lack of generally accepted
standards, all qPCR data on single miRNA expression
were analyzed as unadjusted Ct values and standardized to
miR-16, which fulfilled the following criteria: detectable in
all samples, low dispersion of expression levels and a null
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Page 2 of 7association with APE. To validate miR-16 as a stable inter-
nal reference, its stability during extraction was compared
to that of synthetic cel-miR-39, an miRNA of C. elegans
that is not present in humans. Twenty-five fmol of syn-
thetic cel-miR-39 were spiked in after adding the Denatur-
ing Solution (provided in the mirVana PARIS isolation kit)
to the human plasma samples to avoid degradation by
endogenous RNases, and the RNA was extracted. We
measured the expression of cel-miR-39, miR-16 and miR-
134 in 10 APE patients and 10 healthy controls selected at
random. Afterwards, the expression of miR-134 in APE
patients and healthy controls was compared with miR-16
and cel-miR-39 normalizers, respectively.
Statistical analysis
Data characterized by a normal distribution were
expressed as the mean and standard deviation. Relative
gene expression is widely presented using the 2
-ΔΔCt
method [30]. Relative gene expression involves the gene
of interest data (Ctgene of interest) relative to an internal
control gene (Ctinternal control gene), named delta Ct. The
calculated delta Ct ± SD for the different groups (APE
a n dn o n - A P E )w e r ec o m p a r e dw i t ht h ed e l t aC t±S D
(SD stands for the standard deviation of the average delta
Ct of the group) for the healthy control group and tested
for statistical significance. An independent samples t-test,
Chi-squared test or one-way analysis of variance (one-
way ANOVA) was conducted when appropriate. If a sig-
nificant difference was found, a Bonferroni post-hoc test
or Tamhane’sT 2p o s t - h o ca n a l y s i sw a sc o n d u c t e dt o
determine which groups differed significantly according
to the equal variance criterion. The receiver-operator
characteristic (ROC) curve analysis was performed with
plasma miRNA distinguishing between APE patients and
healthy controls or non-APE patients. The area under
the ROC curve (AUC) was estimated to assess the diag-
nostic accuracy of the miRNA identified. All analyses
were performed using SPSS 13.0, and all statistical tests
were two-sided. For all analyses, p-values < 0.05 were
considered statistically significant.
Results
Expression profiles of miRNAs in the plasma of APE
patients
Thirty differentially expressed plasma miRNAs were iden-
tified in APE patients from healthy controls (Table 1).
From these, microRNA-134 (miR-134) and microRNA-
410 (miR-410) were selected for further validation based
on the changes (> 10-fold) and probability values (P <
0.05).
Validation of candidate miRNAs
The elevation of miR-134 and miR-410 was validated
using TaqMan miRNA qRT-PCR in all participants
(Figure 1A-B). The basic clinical characteristics of APE
patients and non-APE patients are shown in Table 2.
There were no significant differences in gender composi-
tion and age between the APE and non-APE groups. The
change in candidate miRNAs for the APE group or non-
APE group versus the healthy controls is shown in Figure
1 .T h e s ed a t ah a v eb e e nn o r m a l i z e db yt h ee x p r e s s i o n
levels of miR-16, a widely used endogenous reference
miRNA that was also confirmed to be unchanged in our
microarrays. In addition, compared to cel-miR-39, miR-
16 is stable (Additional file 1 Figure S1). Moreover, we
compared the difference in miR-134 expression between
10 APE patients and 10 healthy controls and obtained
the same differences in miR-134 expression regardless of
whether cel-miR-39 or miR-16 were used as the normali-
zer (Figure 2), which further supports that miR-16 is a
stable reference in this study.
Table 1 Alterations in plasma microRNA levels in patients
with an acute pulmonary embolism compared to healthy
controls
microRNA Regulation Fold Change p-value
hsa-miR-134 up 25.392 0.047
hsa-miR-410 up 15.221 0.028
hsa-miR-520g up 6.768 0.048
hsa-miR-485-3p up 6.170 0.018
hsa-miR-362-5p up 5.987 0.047
hsa-miR-382 up 5.501 0.042
hsa-miR-548b-5p up 5.473 0.039
hsa-miR-139-3p up 5.049 0.024
hsa-miR-197 up 4.363 0.015
hsa-miR-574-3p up 4.303 0.024
hsa-miR-190 up 4.031 0.039
hsa-miR-489 up 3.656 0.048
hsa-miR-146a up 3.593 0.030
hsa-miR-320 up 2.470 0.033
hsa-miR-133a up 2.202 0.042
hsa-miR-20a* down 5.924 0.005
hsa-miR-7 down 4.990 0.010
hsa-miR-340* down 4.810 0.039
hsa-miR-923 down 4.255 0.036
hsa-let-7b down 4.068 0.000
hsa-let-7g down 3.512 0.009
hsa-miR-768-3p down 3.166 0.036
hsa-miR-30e down 3.010 0.011
hsa-miR-610 down 2.852 0.045
hsa-miR-126* down 2.799 0.006
hsa-miR-301a down 2.740 0.007
hsa-miR-30d down 2.720 0.004
hsa-miR-30a down 2.212 0.003
hsa-miR-374a down 2.185 0.012
hsa-miR-632 down 1.706 0.043
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Page 3 of 7The plasma miR-134 level was increased in the APE
group compared to both healthy controls and the non-
APE group (Figure 1A). However, plasma miR-410 was
also increased in the non-APE group (Figure 1B), indi-
cating that miR-410, although initially identified by
comparing the APE group to the healthy controls with
miRNA microarrays, was also elevated in the non-APE
group and therefore was not further studied. To confirm
that the assay is reproducible, we also analyzed miR-134
expression level in the plasma (second sampling) col-
lected 1 h after the first sampling of the plasma of three
APE patients. No significant difference in the level of
miR-134 was found between the first sampling and the
second sampling, which indicates that the assay is repro-
ducible (Additional file 2 Figure S2). We also compared
Healthy controls Non-APE APE
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Figure 1 Relative plasma miR-134 and miR-410 expression
levels. (A) and (B) The relative plasma miR-134 (A) and miR-410 (B)
expression level in healthy controls, non-acute pulmonary embolism
(non-APE) patients, and APE patients. The expression levels of miR-
16 normalize the data. *, P < 0.05, comparison of healthy controls
and non-APE patients.
Table 2 Clinical characteristics of acute pulmonary
embolism (APE) patients and non-APE patients
Characteristics APE (n = 32) Non-APE (n = 22)
Age (years) 54.78 ± 16.20 62.27 ± 23.33
Male/female (n/n) 15/17 10/12
Risk stratification
High risk (n) 1 /
Intermediate risk (n) 15 /
Low risk (n) 16 /
Main clinical symptoms
Dyspnea 10 22*
Thoracic pain 11 18*
Clinical signs of DVT 15 0*
Risk factors
Cancer 4 2
Recent surgery (< 30 days) 3 2
Previous DVT 9 0*
Previous PE 8 0*
*, P < 0.05. DVT, Deep vein thrombosis; PE, pulmonary embolism.
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Figure 2 Relative plasma miR-134 expression levels normalized
by cel- miR-39 and hsa-miR-16. (A) and (B) The relative plasma
miR-134 expression levels normalized by cel-miR-39 (A) and hsa-
miR-16 (B) in healthy controls and acute pulmonary embolism
patients. *, P < 0.05, comparison with healthy controls.
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risk APE and low-risk APE and found that the miR-134
level was significantly higher in the high-intermediate-risk
APE patients compared to low-risk patients (Figure 3A).
Diagnostic accuracy of plasma miR-134 for APE
The ROC curve analysis was used to analyze the diag-
nostic accuracy of plasma miR-134. When a comparison
was made between the APE group and the healthy con-
trols, the AUC was 0.833 (95% confidence interval,
0.737 to 0.929; P < 0.001) (Figure 4A). When a compari-
son was made between the APE group and the non-APE
group, the AUC was 0.756 (95% confidence interval,
0.629 to 0.883; P = 0.002). Using 0.00272375 as a cutoff
value for the plasma miR-134 relative expression level,
the sensitivity and specificity of miR-134 for the diagno-
sis of APE in patients reporting dyspnea, chest pain, or
cough were 68.8% and 68.2%, respectively (Figure 4B).
In addition, plasma miR-134 distinguished APE cases
from healthy controls plus non-APE cases with an AUC
of 0.802 (95% confidence interval, 0.702 to 0.901; P <
0.001) (Figure 4C).
Discussion
APE has a nonspecific clinical presentation and is diffi-
cult to diagnose [24]. Although there has been great
progress in the detection and exclusion of APE with the
advent of D-dimer testing and chest CT scans, there is
still a great need for simple and reliable biomarker
detection for objective diagnostic testing of APE [7,31].
In this study, we have identified plasma miR-134 as a
potential biomarker for APE.
Ideally, a biomarker should be reproducible and have
a high sensitivity and specificity for the diagnosis of a
specific disease [10]. miRNAs are exciting potential bio-
markers because they fulfill many of these criteria
[10,16]. Interestingly, miRNAs are present in human
plasma in a remarkably stable form that is protected
from endogenous RNase activity and remain stable even
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Figure 3 Relative plasma microRNA-134 levels in low-risk acute
pulmonary embolism and high-intermediate-risk acute
pulmonary embolism. APE, acute pulmonary embolism; Low APE,
low-risk acute pulmonary embolism; HI-APE, high-intermediate-risk
acute pulmonary embolism; miR-134, microRNA-134. The data are
normalized by the expression levels of microRNA-16. *, P < 0.05,
compared to high-intermediate-risk acute pulmonary embolism
patients.
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Figure 4 The receiver-operator characteristic (ROC) curves for
plasma miR-134 for acute pulmonary embolism (APE). (A-C) The
receiver-operator characteristic (ROC) curves for distinguishing acute
pulmonary embolism (APE) patients from healthy controls, non-APE
patients and healthy controls plus non-APE patients, respectively.
AUC, area under the ROC curve.
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stability, low structural complexity, and lack of post-pro-
cessing modifications make plasma miRNAs ideal bio-
marker candidates [16]. The high sensitivity and
specificity of miRNA detection using qRT-PCR may cre-
ate precise cutoff concentrations for diagnosis [15,17].
To date, the role of plasma miRNAs in APE has not
been reported. As demonstrated by the miR-134 identi-
fied in this study, the use of miRNAs as minimally inva-
sive and robust biomarkers would result in incredible
breakthroughs for the diagnosis of this common disease.
Spiral CT arteriography is widely used in the clinic.
The sensitivity of spiral CT arteriography alone was
83%, whereas the combination of CT arteriography and
CT venography increased the sensitivity to 90%. How-
ever, in those patients with unavailable multidetector
CT, renal failure or an allergy to contrast dye, plasma
miR-134 might be an ideal alternative. In addition, using
plasma miR-134 detection reduces the overall radiation
exposure compared to CT [1,4,24].
We have demonstrated that the plasma miR-134 level
was not affected by non-APE conditions. Plasma miR-
134 could distinguish APE cases from healthy controls or
non-APE cases with an AUC of 0.833 or 0.756, respec-
tively, which indicates the potential for using plasma
miR-134 as a biomarker to diagnose APE. Interestingly, a
recent report indicated that the expression of miR-134
was 3.5-fold higher in the peripheral blood mononuclear
cells of unstable angina pectoris patients compared to
those with stable angina pectoris [33]. In this study, the
plasma miR-134 level in 7 patients with unstable angina
pectoris and 3 with an acute myocardial infarction was
similar to healthy controls. This discrepancy may have
been due to the difference between miRNA levels in
plasma versus peripheral mononuclear cells used in the
original report [33]. In addition, Wong et al. found an
increased expression of miR-134 in patients with squa-
mous cell carcinoma. However, their study used tissue,
whereas our study used plasma [26].
Our study was subject to a number of limitations. First,
the number of APE patients in this study is relatively
small. The results obtained in this small group will
require replication in large, independent studies of APE.
Second, it would be interesting to analyze the relation-
ship of miR-134 to the laboratory findings in both APE
and non-APE patients. For example, it would be helpful
to investigate whether combining the values of D-dimer
and miR-134 would greatly enhance the specificity and
sensitivity for plasma miR-134. Some non-APE patients
in this study did not have D-dimer results because all of
the collected plasma was used to isolate total RNA.
Further studies are needed to resolve this issue. However,
the D-dimer test has a high sensitivity but is non-specific
because it is also positive in patients with infection,
cancer, and other inflammatory diseases [1,24]. The spe-
cificity of miR-134 in diagnosing APE was better than
D - d i m e rt e s ti nt h i ss t u d y .T h i r d ,f u r t h e rw o r ki s
required to determine the additive benefit of miR-134 in
algorithms for APE detection that incorporate other diag-
nostic modalities in prospective fashion. Fourth, whether
circulating miRNAs have a biological function is unclear.
It is commonly speculated that circulating miRs play a
role in maintaining the homeostasis of the circulatory
system [30]. Whether plasma miR-134 can trigger some
pathogenic or protective effects in APE remains uncer-
tain. Finally, the pathobiological mechanism of miR-134
levels and the relationship with APE is unclear. Prior stu-
dies have demonstrated that the release of miRNA from
exosomes, microparticles, or apoptotic bodies may be the
cause of miRNA dysregulation in disease [24,34].
Conclusions
In conclusion, we have found that elevated plasma miR-
134 levels are a potential novel biomarker for the diagno-
sis of APE. Our results provide a basis for future efforts
to develop plasma miRNA-based assays to diagnose APE.
Additional material
Additional file 1: Figure S1 - Relative plasma miR-16 levels in acute
pulmonary embolism patients. APE, acute pulmonary embolism.
Additional file 2: Figure S2 - Relative plasma microRNA-134 levels
in the first sampling and second sampling. n.s., not significant.
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